OSI Is Reconsidering Acquisition Of Eyetech Following Genentech's Lucentis Results
This article was originally published in The Pink Sheet Daily
Executive Summary
OSI says it needs time to "assess the possible impact" of recent data from Eyetech rival Genentech's macular degeneration therapy.